Source:http://linkedlifedata.com/resource/pubmed/id/17446062
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2007-6-18
|
pubmed:abstractText |
Central nervous system (CNS) atypical teratoid/rhabdoid tumours (AT/RT) are among the paediatric malignant tumours with the worst prognosis and fatal outcome. Insulin-like growth factor I receptor (IGF-IR) protects cancer cells from apoptosis induced by a variety of anticancer drugs and radiation. In the present study, IGF-IR was expressed in 8/8 primary AT/RT as detected by immunohistochemistry. Moreover, we found IGF-I and IGF-II mRNA in BT-16 CNS AT/RT cells and IGF-II mRNA in BT-12 CNS AT/RT cells, and autophosphorylated IGF-IR in both cell lines, indicating the potential presence of an autocrine/paracrine IGF-I/II/IGF-IR loop in CNS AT/RT. IGF-IR antisense oligonucleotide treatment of human CNS AT/RT cells resulted in significant down-regulation of IGF-IR mRNA and protein expression, induction of apoptosis, and chemosensitisation to doxorubicin and cisplatin. These studies provide evidence for the influence of IGF-IR on cellular responses to chemotherapy and raise the possibility that curability of selected CNS AT/RT may be improved by pharmaceutical strategies directed towards the IGF-IR.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I,
http://linkedlifedata.com/resource/pubmed/chemical/Oligoribonucleotides, Antisense,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, IGF Type 1
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0959-8049
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
43
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1581-9
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:17446062-Antineoplastic Agents,
pubmed-meshheading:17446062-Apoptosis,
pubmed-meshheading:17446062-Central Nervous System Neoplasms,
pubmed-meshheading:17446062-Child,
pubmed-meshheading:17446062-Child, Preschool,
pubmed-meshheading:17446062-Cisplatin,
pubmed-meshheading:17446062-Down-Regulation,
pubmed-meshheading:17446062-Doxorubicin,
pubmed-meshheading:17446062-Female,
pubmed-meshheading:17446062-Humans,
pubmed-meshheading:17446062-Infant,
pubmed-meshheading:17446062-Insulin-Like Growth Factor I,
pubmed-meshheading:17446062-Male,
pubmed-meshheading:17446062-Oligoribonucleotides, Antisense,
pubmed-meshheading:17446062-Receptor, IGF Type 1,
pubmed-meshheading:17446062-Rhabdoid Tumor,
pubmed-meshheading:17446062-Teratoma
|
pubmed:year |
2007
|
pubmed:articleTitle |
Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells.
|
pubmed:affiliation |
Neuro-Oncology Program, University Children's Hospital of Zurich, Steinwiesstrasse 75, CH-8032 Zurich, Switzerland.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|